“Improving prescription drug affordability for Medicare enrollees is the core of the Inflation Reduction Act, and the next cycle of negotiations will continue to strengthen Medicare for generations to come," Chiquita Brooks-LaSure, administrator of the Centers for Medicare & Medicaid Services, said in the news release.

The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by introducing floors.

Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.

Concern is growing among Democrats after President Donald Trump reversed some of the former president's executive orders, including efforts to reduce prescription drug costs for Medicare and Medicaid beneficiaries.

Experts suggest that most Americans will not experience immediate changes in their out-of-pocket health care expenses.

The rescinded order directed Medicare and Medicaid to test ways to lower drug costs for enrollees. Those tests hadn’t started, so current drug prices are unaffected.

The Trump administration’s first drug pricing action — rescinding a Biden executive order encouraging Medicare to help lower prescription costs — is befuddling drug pricing experts.

As President Donald Trump’s health care agenda for a second term takes shape, it’s becoming clear that many Biden-era policies won’t make the cut.

President Trump rescinded a Biden-era Executive Order that would have lowered the copays for some drugs to $2 for Medicare enrollees.

Drug pricing experts are not sure why rolling back drug pricing initiatives would be a day one priority for President Trump.